Cancer immunotherapy in NSCLC
Based on NCCN and ESMO guidelines
Driver Mut+
TKI
Alternative TKI or
chemotherapy
Front line
?
PD-L1
TPS≥50%
Anti-PDL1/PD1
monotherapy
?
Anti-PDL1/PD1
therapy +
chemotherapy
or immune
doublet
Investigational
only
Sq
NSCLC
Non-sq
NSCLC
Chemotherapy ±
bevacizumab
Chemotherapy
Immunotherapy or
other systemic therapy
Driver Mut-
PD-L1 unknown or
TPS<50%
NSCLC
Stage IV
Mutation
testing
Second line
Novello, et al. Ann Oncol 2016 27(Suppl.5): v1–27; NCCN Guidelines v2.2017
